AnalystsInsight

Nicolas Pauillac (Kepler Capital ): Analyst Track Record and Price‑Target Accuracy

How often Nicolas Pauillac’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 16 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

Key takeaways

  • Nicolas Pauillac ranks #761 of 1,000 analysts in Exent’s scoring (4.7★).
  • 100.0% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 125 days; 57.1% of calls were up 12 months later.
  • Most‑covered stocks: SWX-SDZ, ETR-FYB, EPA-SAN, SWX-COPN.
  • Free on Exent: Nicolas Pauillac’s full record, with ratings 3 days after publication.

Nicolas Pauillac’s track record at a glance

Nicolas Pauillac of Kepler Capital ranks #761 of the 1,000 analysts Exent scores, with a 4.7★ rating and a focus on healthcare. Over a 7‑year lookback, 100.0% of Nicolas’s price targets were reached, 47.6 points above the 52.4% average across all analysts.

MetricNicolas PauillacAll analysts
Price‑target hit rate100.0%52.4%
Median days to hit target125 days91 days
Calls up after 12 months57.1%64.0%
Median 12‑month return of calls+11.9%+13.4%
Hit rate, last 2 years——
Average worst drop after a call−22.3%—
Ratings in the sample16—
Stocks covered29—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetNicolas Pauillac
Under 30 days9.1%
30–90 days36.4%
90–180 days36.4%
Over 180 days18.2%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Nicolas Pauillac covers most

StockRatings in the sample
SWX-SDZ63
ETR-FYB54
EPA-SAN48
SWX-COPN40
ETR-EUZ33
EPA-CVX30
EPA-MEDCL30
EPA-OSE27

In the past year Nicolas’s ratings were 86% Buy, 14% Hold and 0% Sell.

Nicolas Pauillac’s latest ratings

DateStockActionRatingPrice target
May 26, 2026LON-GSKUpgraded: BuyBuy$2516.00
May 26, 2026LON-GSKUpgradedHold → Buy$2516.00
May 11, 2026SWX-CMHCReiterated: BuyBuy$130.00
May 11, 2026SWX-SDZReiterated: BuyBuy$80.00
May 11, 2026SWX-COPNMaintainedBuy$130.00
May 11, 2026SWX-SDZMaintained: BuyBuy$80.00
May 11, 2026SWX-COPNMaintained: BuyBuy$130.00
May 11, 2026SWX-SDZMaintainedBuy$80.00
May 7, 2026SWX-COPNMaintainedBuy$130.00
May 7, 2026SWX-COPNMaintained: BuyBuy$130.00
May 7, 2026SWX-CMHCReiterated: BuyBuy$130.00
May 5, 2026SWX-SDZMaintained: BuyBuy$80.00
  • May 26, 2026
    Stock
    LON-GSK
    Action
    Upgraded: Buy
    Rating
    Buy
    Price target
    $2516.00
  • May 26, 2026
    Stock
    LON-GSK
    Action
    Upgraded
    Rating
    Hold → Buy
    Price target
    $2516.00
  • May 11, 2026
    Stock
    SWX-CMHC
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $130.00
  • May 11, 2026
    Stock
    SWX-SDZ
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $80.00
  • May 11, 2026
    Stock
    SWX-COPN
    Action
    Maintained
    Rating
    Buy
    Price target
    $130.00
  • May 11, 2026
    Stock
    SWX-SDZ
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $80.00
  • May 11, 2026
    Stock
    SWX-COPN
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $130.00
  • May 11, 2026
    Stock
    SWX-SDZ
    Action
    Maintained
    Rating
    Buy
    Price target
    $80.00
  • May 7, 2026
    Stock
    SWX-COPN
    Action
    Maintained
    Rating
    Buy
    Price target
    $130.00
  • May 7, 2026
    Stock
    SWX-COPN
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $130.00
  • May 7, 2026
    Stock
    SWX-CMHC
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $130.00
  • May 5, 2026
    Stock
    SWX-SDZ
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $80.00

Nicolas’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Nicolas Pauillac’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Nicolas Pauillac ranks #761 of 1,000 with a 4.7★ rating. 100.0% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 57.1% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Nicolas Pauillac’s success rate is 53.1% by the ranking source and 100.0% by Exent’s price-target hit-rate backtest, with a median of 125 days to reach a target.

Nicolas Pauillac (Kepler Capital ) covers 29 stocks, mostly in healthcare. The most frequently rated are SWX-SDZ, ETR-FYB, EPA-SAN, SWX-COPN, ETR-EUZ.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.